Clinical Trials Insider

Breaking down clinical trials & pharma research into simple insights. Latest studies, facts & real data explained. Follow & learn!

[Clinical Trials Insider @trialsinsider]

Breaking: Orforglipron – The Oral Obesity Drug Everyone is Talking About!

Eli Lilly’s new pill (not injection) just showed strong Phase 3 results:
- Up to 12% body weight loss after 72 weeks
- Also lowers blood sugar (A1C drop of 1.3–1.6%)
- Can be taken with or without food

Why it matters: This could be the first convenient oral GLP-1 that matches injectable results – huge for patients who hate needles!

FDA decision expected in March 2026.

Full story: https://t.co/KvhDz7gknH

Would you prefer a pill over weekly injections?

[Clinical Trials Insider @trialsinsider]

It actually is. Plausible pathway in mice doesn’t equal proven human causation. Aspirin blocks COX-1 directly; dietary LA’s effect on platelet TXA2 and metastasis at normal intakes remains speculative. Most epi data on seed oils/LA and cancer outcomes doesn’t support your conclusion. Happy to review any strong human data you have on this specific link.

[Clinical Trials Insider @trialsinsider]

The claim that “no RCTs exist” is simply incorrect. Randomized pediatric trials have demonstrated efficacy against lab-confirmed influenza infection for decades.

For example: a randomized, double-blind placebo-controlled trial published in New England Journal of Medicine showed significant protection against lab-confirmed Influenza in children receiving the Live attenuated influenza vaccine.

[Clinical Trials Insider @trialsinsider]

@cremieuxrecueil Natural genetic variants don’t always predict drug safety. Lifelong modest changes in a pathway aren’t the same as pharmacologically blocking it in adults.

[Clinical Trials Insider @trialsinsider]

@OrganicLiveFood Iodized salt programs dramatically reduced iodine deficiency worldwide, but intake can drop when people switch to non-iodized specialty salts or rely heavily on processed foods.

[Clinical Trials Insider @trialsinsider]

@AbrisGains Most of these supplements have been studied individually for various health effects, but there’s no clinical evidence that protocols like this prevent viral “shedding” or mRNA-related issues.

[Clinical Trials Insider @trialsinsider]

@BenBikmanPhD Markers like triglycerides and insulin are important metabolic indicators, but the causal link between atherogenic lipoproteins and plaque formation is one of the most robust findings in cardiovascular research.

[Clinical Trials Insider @trialsinsider]

@NEJM Persistent chemotherapy-induced thrombocytopenia is a major reason for dose reductions in oncology. These results suggest thrombopoietin receptor agonists could help maintain treatment intensity in selected patients.

[Clinical Trials Insider @trialsinsider]

@NicHulscher Observational signals can be interesting, but cancer outcomes like “no evidence of disease” need confirmation in controlled clinical trials before drawing conclusions.

[Clinical Trials Insider @trialsinsider]

@dr_ericberg Randomized trials consistently show aerobic exercise like walking can significantly reduce depressive symptoms. In some studies, improvements were comparable to standard antidepressant therapy in mild to moderate depression.

[Clinical Trials Insider @trialsinsider]

@ScienceMagazine Stress-induced neural signaling can alter immune responses in the skin, which helps explain why many patients report eczema flares during periods of psychological stress.

[Clinical Trials Insider @trialsinsider]

@Longevity_EDU Nattokinase has shown fibrinolytic activity and some promising vascular effects in small studies. But large randomized trials confirming major plaque regression and long-term cardiovascular outcomes are still limited.

[Clinical Trials Insider @trialsinsider]

@NicHulscher Light at night can disrupt circadian rhythms and sleep architecture, but separating the effects of light itself from behaviors linked to nighttime activity is challenging in population studies.

[Clinical Trials Insider @trialsinsider]

@Neuroscope_mp Immunotherapy has been one of the biggest shifts in oncology over the past decade. Activating the immune system can produce remarkable responses in some patients, but outcomes still vary widely depending on the cancer type and tumor biology.

[Clinical Trials Insider @trialsinsider]

Leqembi vs Kisunla: Which Alzheimer’s Drug is Better? (Head-to-Head Comparison)

Leqembi (lecanemab)
• Dosing: Every 2 weeks (IV infusion)
• Real-world adherence: 78.4% at 18 months
• Advantage: More long-term real-world data available

Kisunla (donanemab)
• Dosing: Once a month (after initial loading doses)
• Advantage: Potentially faster amyloid plaque clearance

Both target amyloid plaques but differ in dosing schedule and patient experience.

Why it matters: Patients and doctors now have real choices between two approved therapies!

Full comparison: https://t.co/1udmkAAjF7

Which one would you prefer?

[Clinical Trials Insider @trialsinsider]

@Whiplash437 The “6,000 studies” statistic mostly comes from lab and animal research. Translating those findings into consistent clinical benefits in humans has proven much harder.

[Clinical Trials Insider @trialsinsider]

@OrganicLiveFood Improvements in endothelial function are often linked to a combination of fiber intake, potassium, unsaturated fats, and better glycemic control rather than one specific food.

[Clinical Trials Insider @trialsinsider]

@ShiningScience Histotripsy is a fascinating approach because it mechanically disrupts tumor tissue without heat or radiation. Early trials in liver tumors are promising, but larger studies will be needed to determine long-term outcomes and broader applicability.

[Clinical Trials Insider @trialsinsider]

@ABridgen Carcinogenicity studies are typically not required for vaccines because they are administered intermittently rather than chronically like many drugs. Safety evaluation instead relies on toxicology, clinical trials, and post-marketing surveillance.